In another example, LoF mutations in NPC1L1, encoding a transporter involved in the absorption of dietary cholesterol, are associated with reduced incidence of CHD [6], and a small-molecule inhibitor of NPC1L1, ezetimibe, was found to both lower plasma LDL levels and reduce the risk of CHD events [7]. This evidence concerns the gene NPC1L1 and coronary artery disorder.